Skip to content

Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder

Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03683472
Enrollment
65
Registered
2018-09-25
Start date
2019-05-20
Completion date
2019-10-17
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders

Keywords

Anxiety, worry, mindfulness, meditation

Brief summary

The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for individuals with generalized anxiety disorder.

Detailed description

The study aims are to (1) develop and refine Unwinding Anxiety for individuals with generalized anxiety disorder, (2) determine user engagement and acceptability as well as measure effect sizes of the program vs. treatment as usual, and (3) preliminarily test mechanisms of action. The knowledge gained will set the stage for a number of future studies related to further elucidating the mechanisms of mindfulness, and the clinical efficacy and utility of this type of training delivered via digital therapeutics in general. Specifically, this study will provide necessary variances for powering larger phase 2 studies.

Interventions

BEHAVIORALUnwinding Anxiety Phone App

The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety

Sponsors

Brown University
CollaboratorOTHER
MindSciences, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Owns a smart phone * GAD - 7 is equal to or greater than 10

Exclusion criteria

* If using psychotropic medication - not on a stable dosage for at least 6 weeks * Medical disorder of the severity that would interfere with ability to participate * Not being fluent in English (due to instructions provided in English) * As needed use (i.e. prn) of benzodiazepines * Psychotic disorder, * Previous MT (e.g. MBSR, other Claritas MindSciences training programs).

Design outcomes

Primary

MeasureTime frameDescription
UA Program engagementTwo monthsNumber of modules completed
Change in worryBaseline, two monthsPenn State Worry Questionnaire (PSWQ)

Secondary

MeasureTime frameDescription
Change in non-reactivity & awarenessBaseline, two monthsFive Facet Mindfulness Questionnaire - Non-Reactivity subscale (FFMQ)
UA Program AcceptabilityTwo monthsNet Promoter Score (NPS)

Other

MeasureTime frameDescription
Change in anxietyBaseline, two monthsGeneralized Anxiety Disorder - 7 items (GAD-7)
Change in self-regulationBaseline, two monthsMultidimensional Assessment of Interoceptive Awareness (MAIA)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026